Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Capital Expenditures
Gensight Biologics SA
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Capital Expenditures
-€11k
|
CAGR 3-Years
18%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Capital Expenditures
-€26m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Capital Expenditures
-€2.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
49%
|
CAGR 10-Years
0%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Capital Expenditures
-€1.2m
|
CAGR 3-Years
-111%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-13%
|
|
|
Inventiva SA
PAR:IVA
|
Capital Expenditures
-€565k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Capital Expenditures
-€3.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Capital Expenditures?
Capital Expenditures
-11k
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Capital Expenditures amounts to -11k EUR.
What is Gensight Biologics SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
45%
Over the last year, the Capital Expenditures growth was 89%. The average annual Capital Expenditures growth rates for Gensight Biologics SA have been 18% over the past three years , 45% over the past five years .
You don't have any saved screeners yet